{"id":1290,"date":"2018-09-14T15:56:00","date_gmt":"2018-09-14T13:56:00","guid":{"rendered":"https:\/\/lensounds.com\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/"},"modified":"2018-09-14T15:56:00","modified_gmt":"2018-09-14T13:56:00","slug":"211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/","title":{"rendered":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome"},"content":{"rendered":"

Abstract<\/h2>\n

This Phase I\/II dose-escalation trial evaluates 211<\/sup>At-BC8-B10 (an anti-CD45 \u03b1-particle\u2013emitting monoclonal antibody) as a conditioning agent before haploidentical hematopoietic cell transplantation (HCT) for patients with relapsed or refractory high-risk acute leukemias and myelodysplastic syndromes (MDS). Eligible patients include those with AML, ALL, MPAL, or high-risk MDS (age 18\u201375 years). The preparative regimen consists of 211<\/sup>At-BC8-B10 (Day -8, dose-escalation), fludarabine (Days -6 to -2), cyclophosphamide (Days -6, -5), and total-body irradiation (Day -1), followed by PBSC or bone marrow infusion (Day 0). GVHD prophylaxis includes post-transplant cyclophosphamide (Days 3-4), mycophenolate mofetil (Days 5-35), and tacrolimus (Days 5-180). The primary endpoint is grades III\/IV regimen-related toxicity to determine maximum tolerated dose. Secondary endpoints include remission achievement, engraftment rates, donor chimerism, non-relapse mortality, GVHD incidence, and overall\/disease-free survival at 2 years. This approach combines the superior cytotoxic properties of \u03b1-particle therapy with haploidentical HCT’s immunologic advantages and PTCy-based GVHD prevention, offering the potential to improve outcomes in this patient population with otherwise poor prognosis.<\/p>\n

Publication Information<\/h2>\n

Source:<\/strong> ClinicalTrials.gov<\/p>\n

Trial Registration Date:<\/strong> September 14, 2018<\/p>\n

Last Update Posted:<\/strong> October 16, 2025<\/p>\n

Trial ID:<\/strong> NCT03670966<\/p>\n

ClinicalTrials.gov Link:<\/strong> https:\/\/clinicaltrials.gov\/study\/NCT03670966<\/a><\/p>\n

Authors<\/h2>\n

Sponsor:<\/strong> Fred Hutchinson Cancer Center<\/p>\n

Principal Investigator:<\/strong> Phuong Vo, MD<\/p>\n

Contact:<\/strong> Phone: 206-667-2749; Email: ptvo@fredhutch.org<\/p>\n

Institutional Affiliation:<\/strong> Fred Hutch\/University of Washington Cancer Consortium, Seattle, Washington, United States<\/p>\n

Phase:<\/strong> Phase I\/II<\/p>\n

Estimated Enrollment:<\/strong> 30 patients<\/p>\n

Study Timeline:<\/strong> July 10, 2019 \u2013 March 20, 2029 (estimated)<\/p>\n

Funding:<\/strong> National Cancer Institute (NCI); NIH Grants P30CA015704 and P01CA078902<\/p>\n","protected":false},"excerpt":{"rendered":"

ClinicalTrials.gov ID: NCT03670966 – Sponsor: Fred Hutchinson Cancer Center – ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT03670966<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[49],"class_list":["post-1290","science","type-science","status-publish","hentry","science_category-at-211-publications"],"yoast_head":"\n211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco\" \/>\n<meta property=\"og:description\" content=\"ClinicalTrials.gov ID: NCT03670966 - Sponsor: Fred Hutchinson Cancer Center - ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT03670966\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\\\/\",\"name\":\"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2018-09-14T13:56:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco","og_description":"ClinicalTrials.gov ID: NCT03670966 - Sponsor: Fred Hutchinson Cancer Center - ClinicalTrials.gov Link: https:\/\/clinicaltrials.gov\/study\/NCT03670966","og_url":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/","og_site_name":"Atonco","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/","url":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/","name":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2018-09-14T13:56:00+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/211at-bc8-b10-followed-by-donor-stem-cell-transplant-in-treating-patients-with-relapsed-or-refractory-high-risk-acute-leukemia-or-myelodysplastic-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/1290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1290"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=1290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}